Key facts
- This page summarizes Robert Langer's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 May 2022, 16:45.
Robert Langer - 28 Apr 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Director
- Issuer ticker
- MRNA
- Reported as of
- 28 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 May 2022, 16:45:52 UTC
- Prior SEC filing
- 12 Jan 2022
- Next SEC filing
- 17 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Langer filed Form 4 for Moderna, Inc. (MRNA) on 02 May 2022.
Change
- Previous filing in this sequence was filed on 12 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +703
- Change %
- +0.01%
- Price
- $0.000000
- Shares after
- 11,467,664
- Date
- 28 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14,132
- Date
- 28 Apr 2022
- Ownership
- By: Michael D. Langer Irrevocable Trust u/d/t dated 12/14/95
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14,132
- Date
- 28 Apr 2022
- Ownership
- By: Samuel A. Langer Irrevocable Trust u/d/t dated 12/14/95
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 14,132
- Date
- 28 Apr 2022
- Ownership
- By: Susan K. Langer Irrevocable Trust u/d/t dated 12/14/95
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -703
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 703
- Exercise price
- $0.000000
- Footnotes
- F1, F2
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,415
- Change %
- Price
- $0.000000
- Shares after
- 5,415
- Date
- 28 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,415
- Exercise price
- $142.52
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
The shares subject to this restricted stock unit award vested in full on April 28, 2022.
Footnote F3
This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.